Casper Rokx
Erasmus Medical Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Casper Rokx as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:57 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07384624 · Combining Latency Reversing Agents to Address the HIV ReservoirErasmus Medical Center · not yet recruiting · HIV (Human Immunodeficiency Virus), HIV -1 Infection · principal investigator
- N/ANCT06900829 · #AWARE.HIV Europe: Supporting Healthcare Professionals to Find Undiagnosed HIV in European Hospitals: An Effectiveness-implementation Trial.Casper Rokx · recruiting · HIV Infection, HIV, Stigma · principal investigator
- N/ANCT05215704 · Ex Vivo Characterization and Targeting of the Latent HIV Infected Reservoir to Cure HIVErasmus Medical Center · recruiting · HIV Infections, HIV-1-infection, HIV-2 Infection · principal investigator
- N/ANCT04888754 · A Prospective Cohort for ex Vivo Cure Studies With Chronic HIV Infected Patients in the NetherlandsErasmus Medical Center · active not recruiting · HIV Infections, HIV-1-infection, HIV-2 Infection · principal investigator
- Ph1/Ph2NCT03525730 · LRAs United as a Novel Anti-HIV Strategy.Erasmus Medical Center · completed · HIV-1-infection · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:57 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:57 UTC. The ranking covers the 200 most relevant of 12 PubMed records, and a shared surname and initials can bring in a namesake. All 12 on PubMed
- Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection.Nat Commun · 2021135 citationsRCR 6.4
- Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial.Lancet HIV · 2017105 citationsRCR 4.3
- Outpatient convalescent plasma therapy for high-risk patients with early COVID-19: a randomized placebo-controlled trial.Clin Microbiol Infect · 202330 citationsRCR 2.2
- Predictors of virological failure in HIV-1-infected patients switching to dolutegravir maintenance monotherapy.HIV Med · 201919 citationsRCR 0.9
- Effectiveness of a community-based intervention to improve nutrition in young children in Senegal: a difference in difference analysis.Public Health Nutr · 200918 citationsRCR 0.7
- The BAF complex inhibitor pyrimethamine reverses HIV-1 latency in people with HIV-1 on antiretroviral therapy.Sci Adv · 202312 citationsRCR 1.2
- The dolutegravir/valproic acid drug-drug interaction is primarily based on protein displacement.J Antimicrob Chemother · 202110 citationsRCR 0.9
- Short communication: Lipids and cardiovascular risk after switching HIV-1 patients on nevirapine and emtricitabine/tenofovir-DF to rilpivirine/emtricitabine/tenofovir-DF.AIDS Res Hum Retroviruses · 20159 citationsRCR 0.3
- The efficacy, pharmacokinetics, and safety of a nevirapine to rilpivirine switch in virologically suppressed HIV-1-infected patients.J Acquir Immune Defic Syndr · 20155 citationsRCR 0.2
- Changes in renal, bone, lipid, and inflammation markers in HIV-1 patients after combination antiretroviral therapy simplification to dolutegravir monotherapy.Int J STD AIDS · 20194 citationsRCR 0.2